Pfizer Oncology Data Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting 2016

The embargo on most data will lift on Wednesday, May 18, at 5:00 p.m. EDT unless otherwise noted.

At the American Society of Clinical Oncology (ASCO) Annual Meeting 2016, multiple abstracts will be presented highlighting clinical progress for 10 Pfizer Oncology assets. The presentations span multiple tumor types and mechanisms of action.1

Avelumab:


(abstract 4514) Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN Solid Tumor phase 1b trial: analysis of safety, clinical activity, and PD-L1 expression. Apolo A. Monday, June 6. Session Type: Poster Discussion. Presentation Time: 1:00 p.m. – 4:30 p.m. CDT. Location: Hall A. Discussion Time: 4:45 p.m. – 6:00 p.m. CDT. Location: Arie Crown Theater. Poster Board: #137.

(abstract 4516) Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced adrenocortical carcinoma from the JAVELIN Solid Tumor phase 1b trial: safety and clinical activity. Le Tourneau C. Monday, June 6. Session Type: Poster Discussion. Presentation Time: 1:00 p.m. – 4:30 p.m. CDT. Location: Hall A. Discussion Time: 4:45 p.m. – 6:00 p.m. CDT. Location: Arie Crown Theater. Poster Board: #139.

(abstract 4009) Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from the JAVELIN Solid Tumor phase 1b trial: analysis of safety, clinical activity. Chung H. Saturday, June 4. Session Type: Poster Discussion. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Discussion Time: 3:00 p.m. – 4:15 p.m. CDT. Location: Hall D1. Poster Board: #1.

(abstract TPS4134) Maintenance therapy with avelumab (MSB0010718C; anti-PD-L1) vs continuation of first-line chemotherapy in patients with unresectable, locally advanced or metastatic gastric cancer: the phase 3 JAVELIN Gastric 100 trial. Moehler M. Saturday, June 4. Session Type: Poster Session. Presentation Time: 8:00 am – 11:30 am. CDT. Location: Hall A. Poster Board: #124b.

(abstract 5533) Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase 1b trial: safety and clinical activity. Disis M. Monday, June 6. Session Type: Poster Session. Presentation Time: 1:00 p.m. – 4:30 p.m. CDT. Location: Hall A. Poster Board: #356.

(abstract 3055) Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced cancer: safety data from 1300 patients enrolled in the phase 1b JAVELIN Solid Tumor trial. Kelly K. Sunday, June 5. CDT. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: #377.
(Abstract 9036) Avelumab (MSB0010718C; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN Solid Tumor phase 1b trial: safety, clinical activity, and PD-L1 expression. Verschraegen C. Saturday, June 4. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: #359.

(Abstract TPS3106) Avelumab (MSB0010718C; anti-PD-L1) in combination with other cancer immunotherapies in patients with advanced malignancies: the phase 1b/2 JAVELIN Medley study. Ribas A. Sunday, June 5. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: #422b.

(Abstract TPS9105) Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: the phase 3 JAVELIN Lung 100 trial. Reck M. Saturday, June 4. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: #425a.

(Abstract TPS4135) Avelumab (MSB0010718C; anti-PD-L1) + best supportive care (BSC) vs BSC ± chemotherapy as third-line treatment for patients with unresectable, recurrent, or metastatic gastric cancer: the phase 3 JAVELIN Gastric 300 trial. Bang Y. Saturday, June 4. CDT. Session Type: Poster Session. Presentation Time: 8:00 am – 11:30 am. CDT. Location: Hall A. Poster Board: #125a.


(No Abstract Number) Systematic literature review of efficacy, safety, and tolerability outcomes of interventions in patients with distant metastatic Merkel cell carcinoma. Nghiem P. Publication only.

(No Abstract Number) Efficacy and tolerability of anti-programed death-ligand 1 (PD-L1) antibody (ab), Avelumab (Av) in advanced thymic epithelial tumors (TETs). Rajan A. Publication only.

Axitinib:

(No Abstract Number) Treatment patterns and costs associated with axitinib and everolimus treatment for renal cell carcinoma: a commercial health claims analysis. MacLean E. Publication Only.

Crizotinib:

(Abstract 11509) Crizotinib in Children and Adolescents with Advanced ROS1, MET, or ALK-rearranged Cancer: Results of the Acse Phase II Trial. Vassal G. Monday, June 6. Session Type: Clinical Science Symposium. Presentation Time: 9:45 a.m. – 9:57 a.m. CDT. Location: S404.

(Abstract 9022) Phase II Study of Crizotinib in East Asian Patients (pts) with ROS1-Positive Advanced Non-Small Cell Lung Cancer (NSCLC). Goto K. Saturday, June 4. Session Type: Poster Discussion. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Discussion Time: 3:00 p.m. – 4:15 p.m. CDT. Location: E354b. Poster Board: #345.

(Abstract 9058) Phase 3 study of first-line crizotinib vs pemetrexed-cisplatin/carboplatin (PCC) in East Asian patients (pts) with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC). Lu S. Saturday, June 4. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: #381.

(Abstract 9062) ALK FISH positivity and crizotinib efficacy in patients (pts) with non-small cell lung cancer (NSCLC). Soria J. Saturday, June 4. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: #385.

(Abstract 9066) Crizotinib vs chemotherapy in ALK+ advanced non-small cell lung cancer (NSCLC): Final survival results from PROFILE 1007. Shaw A. Saturday, June 4. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: #389.

**Inotuzumab:**

(Abstract 7027) Patient-reported outcomes (PRO) from a global phase 3 randomized controlled trial (RCT) of inotuzumab ozogamicin (InO) vs standard care (SC) for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). Kantarjian H. Monday, June 6. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: #19.

(Abstract 7028) Inotuzumab ozogamicin (InO) for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) in the phase III INO-VATE trial: Efficacy and safety by prior therapy. DeAngelo D. Monday, June 6. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: #20.

(Abstract 7029) Efficacy and safety of inotuzumab ozogamicin (InO) in older patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) enrolled in the phase 3 INO-VATE trial. Jabbour E. Monday, June 6. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: #21.

**Lorlatinib** *(PF-3922):*

(Abstract 9009) Safety and Efficacy of Lorlatinib (PF-06463922) from the Dose-Escalation Component of a Study in Patients with Advanced ALK+ or ROS1+ Non-Small Cell Lung Cancer (NSCLC). Solomon B. Monday, June 6. Session Type: Clinical Science Symposium. Presentation Time: 1:15 p.m. – 1:27 p.m. CDT. Location: Hall D2.

**Palbociclib:**

(Abstract 512) Efficacy of Palbociclib Plus Fulvestrant (P+F) in Patients (pts) with Metastatic Breast Cancer (MBC) and ESR1 Mutations (mus) in Circulating Tumor DNA (ctDNA). Turner N. Friday, June 3. Session Type: Clinical Science Symposium. Presentation Time: 5:18 p.m. – 5:30 p.m. CDT. Location: Hall D1.

(Abstract 524) Palbociclib (PAL) in Combination with Fulvestrant (F) in Pre-/Peri-Menopausal (PreM) Women with Metastatic Breast Cancer (MBC) and Prior Progression on Endocrine Therapy – Results from Paloma-3. Loibl S. Sunday, June 5. Session Type: Poster Discussion. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: #12. Discussion Time: 11:30 a.m. – 12:45 p.m. CDT. Location: Hall D2.

(Abstract 561) Real-world use of first-line chemotherapy in post-menopausal patients with HR-positive HER2-negative metastatic breast cancer (mBC) in a US community oncology network. Patt D. Sunday, June 5. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: #49.

(Abstract 554) Breast cancer specific quality of life in HR+/HER2- advanced/metastatic breast cancer patients in a real-world setting. Wood R. Sunday, June 5. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: #49.

(Abstract TPS6102) An international, multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 2 study of palbociclib (an oral CDK4/6 inhibitor) plus cetuximab in patients with recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Keam B. Saturday, June 4. Session Type: Poster Session. Presentation Time: 1:00 p.m. – 4:30 p.m. CDT. Location: Hall A. Poster Board: #423b.


Pan-RCC


Early-Pipeline Assets

Utomilumab* (4-1BB; PF-2566):

**Gedatolisib* (PF-2384):**

(Abstract 2566) Phase I study of the PI3K/mTOR inhibitor gedatolisib (PF-05212384) in combination with docetaxel, cisplatin, and dacomitinib. Wainberg Z. Sunday, June 5. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: #266.

**OX40 mAb (PF-8600):**

(Abstract 3079) First in human (FIH) study of an OX40 agonist monoclonal antibody (mAb) PF-04518600 (PF-8600) in adult patients (pts) with select advanced solid tumors: Preliminary safety and pharmacokinetic (PK)/pharmacodynamic results. Hamid O. Sunday, June 5. Session Type: Poster Session. Presentation Time: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Poster Board: #401.


**Glasdegib* (PF-9913):**


* = Proposed non-proprietary name

###

---